Delcath Systems, Inc. (DCTH) Stock Price & Analysis
Delcath Systems, Inc. (DCTH) fell 1.69% to USD 12.22 as of July 25, 2026 at 15:42 UTC, according to Nexqual real-time market data.
DCTH last closed at USD 12.43; the session ranged USD 12.13–12.57 on volume of 298,907 shares. Market capitalization is $421.85M, with a 52-week range of USD 8.12–13.74 (NCM). Source: Nexqual, July 25, 2026 at 15:42 UTC.
Key Statistics (as of July 25, 2026 at 15:42 UTC)
| Price | USD 12.22 |
|---|---|
| Change | ▼ 1.69% (down) |
| Previous Close | USD 12.43 |
| Open | USD 12.56 |
| Day Range | USD 12.13 – 12.57 |
| 52-Week Range | USD 8.12 – 13.74 |
| Volume | 298,907 shares |
| Market Cap | $421.85M |
| Exchange | NCM |
Technical Analysis (DCTH)
Nexqual's technical model rates DCTH "BUY" based on 5 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 15:42 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 48.1 (neutral) |
| vs SMA50 | Above (USD 11.95) |
| MACD | 0.14 (positive) |
Analyst Ratings (DCTH)
Wall Street analysts rate DCTH "Strong Buy" based on 5 analysts, with a mean price target of USD 21.55 (range USD 17–29.76), per Nexqual as of July 25, 2026 at 15:42 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 21.55 |
| High Target | USD 29.76 |
| Low Target | USD 17 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (DCTH)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.09 |
| Revenue Estimate | $26.26M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.03 vs est -0.09 ▲ beat |
| 2025-12-31 | USD -0.05 vs est -0.03 ▼ miss |
| 2025-09-30 | USD 0.02 vs est -0.09 ▲ beat |
| 2025-06-30 | USD 0.07 vs est 0.03 ▲ beat |
Source: Nexqual, July 25, 2026 at 15:42 UTC.
Financials & Fundamentals (DCTH)
| Total Revenue | $90.44M |
|---|---|
| Revenue Growth (YoY) | +26.30% |
| Gross Margin | +85.97% |
| Operating Margin | -6.55% |
| Profit Margin | +0.62% |
| ROE | +0.58% |
| Debt / Equity | 0.81 |
| Current Ratio | 11.24 |
| Total Cash | $89.30M |
| Total Debt | $907,000 |
| Free Cash Flow | $19.65M |
Source: Nexqual, July 25, 2026 at 15:42 UTC.
Financial Health Score (DCTH)
Nexqual rates Delcath Systems, Inc.'s overall financial health "Solid" across five dimensions, as of July 25, 2026 at 15:42 UTC.
| Growth | Strong — Revenue +129% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 86%, operating -7% |
| Balance Sheet | Strong — $89M cash, no debt |
| Cash Flow | Strong — FCF $20M, 23% margin |
| Efficiency | Weak — ROE 1%, ROA -1.0% |
Ownership (DCTH)
| Insider Ownership | +8.13% |
|---|---|
| Institutional Ownership | +49.06% |
| Shares Outstanding | 34.52M |
| Float | 28.60M |
| Short % of Float | +8.50% |
Source: Nexqual, July 25, 2026 at 15:42 UTC.
Leadership (DCTH)
Delcath Systems, Inc. is led by Gerard J. Michel MBA, MS (age 62), CEO & Director, per Nexqual as of July 25, 2026 at 15:42 UTC.
| CEO & Director | Gerard J. Michel MBA, MS (age 62) |
|---|---|
| Chief Operating Officer | Martha S. Rook (age 54) |
| Chief Financial Officer | Sandra Pennell (age 46) |
| Senior Vice President of Clinical Operations & Medical Affairs | Johnny John (age 60) |
| Senior Vice President of Interventional Oncology | Michael Brunner |
From Delcath Systems, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe.
- The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
- Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma.
- The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BGMSP | Bio Green Med Solution Inc. | USD 3.5 | ▲ 0% |
| IDXG | Interpace Biosciences, Inc. | USD 1.46 | ▼ 3.31% |
| IMUC | EOM Pharmaceutical Holdings Inc | USD 0.21 | ▼ 15.73% |
| CSCID | COSCIENS Biopharma Inc | USD 5.5 | ▲ 1.85% |
| CVM | Cel-Sci Corporation | USD 1.18 | ▼ 4.07% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 15:42 UTC. This page is informational and not investment advice.